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Abstract
Background: Allele frequencies reported from public databases or articles are mostly based on
small sample sizes. Differences in genotype frequencies by age, race and sex have implications for
studies designed to examine genetic susceptibility to disease.
In a community-based cohort of 9,960 individuals, we compared the allele frequencies of 49 single
nucleotide polymorphisms (SNPs) of genes involved in inflammatory pathways to the frequencies
reported on public databases, and examined the genotypes frequencies by age and sex. The genes
in which SNPs were analyzed include CCR2, CCR5, COX1, COX2, CRP, CSF1, CSF2, IFNG, IL1A,
IL1B, IL2, IL4, IL6, IL8, IL10, IL13, IL18, LTA, MPO, NOS2A, NOS3, PPARD, PPARG, PPARGC1
and TNF.
Results: Mean(SD) age was 53.2(15.5); 98% were Caucasians and 62% were women. Only 1 out
of 33 SNPs differed from the SNP500Cancer database in allele frequency by >10% in Caucasians (n
= 9,831), whereas 12 SNPs differed by >10% (up to 50%) in African Americans (n = 105). Two out
of 15 SNPs differed from the dbSNP database in allele frequencies by >10% in Caucasians, and 5
out of 15 SNPs differed by >10% in African Americans. Age was similar across most genotype
groups. Genotype frequencies did not differ by sex except for TNF(rs1799724), IL2(rs2069762),
IL10(rs1800890), PPARG(rs1801282), and CRP(rs1800947) with differences of less than 4%.
Conclusion: When estimating the size of samples needed for a study, particularly if a reference
sample is used, one should take into consideration the size and ethnicity of the reference sample.
Larger sample size is needed for public databases that report allele frequencies in non-Caucasian
populations.
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Background
Chronic inflammation has been implicated in a wide vari-
ety of diseases, including cardiovascular disease, cancer,
diabetes, neurological disorders, arthritis, among others
[1-8]. Knowledge of genetic variations that influence
inflammatory responses is important for assessing disease
risk and identifying preventive strategies.
Several genes have been found to be involved in inflam-
matory responses. Examples are genes coding for inter-
leukins (ILs) [9], tumor necrosis factors (TNFs) [9],
cyclooxygenases (COX1 and COX2) [9], nitric oxide syn-
thases (iNOS and eNOS) [10,11], peroxisome prolifera-
tor-activated receptors (PPARs) [12], CC chemokine
receptors (CCR2, CCR5) [13,14], myeloperoxidase
(MPO) [15], interferon-gamma (IFNG) [16], colony-stim-
ulating factors (CSF1, CSF2) [17], lymphotoxin α (LTA)
[18], and C-reactive protein (CRP) [18].
When designing a study to investigate genetic susceptibil-
ity to diseases, information on the allele frequencies of
single nucleotide polymorphisms (SNPs) in the source
population is crucial for ensuring sufficient statistical
power. To date, the estimation for allele or genotype fre-
quencies of candidate genes has been primarily based on
limited numbers of individuals. For example, the
SNP500Cancer database, a useful resource often used for
referencing sequences and allele frequencies of validated
SNPs, were based on 102 anonymous individuals with
self-described heritage (24 African Americans, 31 Cauca-
sians, 23 Hispanics, and 24 Pacific Rim heritages) [19].
On the dbSNP database, summary allele frequencies were
calculated based on data from various ethnic groups, and
often, several hundreds of samples were included [20].
The International HapMap Project analyzed 270 individ-
uals, including 30 sets of samples from two parents and
an adult child in Yoruba people of Ibadan, Nigeria, 45
unrelated individuals from Tokyo, 45 unrelated individu-
als from Beijing, and 30 U.S. trios with northern and west-
ern European ancestry [21]. Published studies of genetic
polymorphisms have included no more than a few hun-
dreds of individuals. The limited sample sizes make for
uncertainties in estimating the allele frequencies in the
general population.
Age and sex are often used as matching factors in epidemi-
ological association studies because in most cases, they
are associated with disease risk or survivorship. When
genotype frequency is associated with age or sex, by
matching on these factors in case-control studies, one
would make the genotype frequency artificially similar
between cases and controls. Under this circumstance,
over-matching may occur.
To assess how allele frequencies reported on public data-
bases are commensurate with the allele frequencies in the
general population, we compared the allele frequencies of
selected SNPs in candidate genes involved in inflamma-
tory pathways in a large, community-based population in
Washington County, Maryland to the allele frequencies
reported from SNP500Cancer database, and if unavaila-
ble from SNP500Cancer, the dbSNP database. In addi-
tion, we compared the genotype frequencies among age
and sex groups to explore whether overmatching by age or
sex in an association study of genetic polymorphisms and
disease risk may be of concern. The candidate genes
included were CCR2, CCR5, COX1, COX2, CRP, CSF1,
CSF2, IFNG, IL1A, IL1B, IL2, IL4, IL6, IL8, IL10, IL13,
IL18, LTA, MPO, NOS2A, NOS3, PPARD, PPARG,
PPARGC1 and TNF.
Results
Characteristics of the study population, the Odyssey and
CLUE II subcohort, were presented in Table 1. The Odys-
sey participants were older than the CLUE II subcohort,
reflecting the fact that individuals in the Odyssey had par-
ticipated in the CLUE I 15 years prior to CLUE II. The
Odyssey cohort also had more women, higher body mass
index (BMI), and more years of school education.
Among the 33 SNPs that were both reported by the
present study and the SNP500 Cancer Database, the allele
frequency of only 1 SNP differed by more than 10% in
Caucasians, whereas the allele frequencies of 7 SNPs dif-
fered by 11–20%, 4 SNPs differed by 21–30%, and 1 SNP
differed by 50% in African Americans (Table 2, see Addi-
tional file 1). Among the 15 SNPs that were also reported
on the dbSNP database, 2 SNPs differed by more than 10–
20% in Caucasians, whereas in African Americans, the
allele frequencies of 5 SNPs differed by 10–20%. Most
SNPs followed the Hardy-Weinberg equilibrium with the
exceptions of CCR5 (rs333), COX1 (rs3842787), CRP
(rs1800947), CSF2 (rs1469149), IL1B (rs16944), IL4
(rs2243250), IL18 (rs187238), LTA (rs2857713), LTA
(rs3093543), and NOS2A (rs2297518) (Table 2; see Addi-
tional file 1).
Age was similar among the genotype groups with a few
exceptions (Table 3; see Additional file 2). Specifically,
statistically significant differences of one to three years of
age were observed for the genotypes of TT vs. CC of IL4
(rs2243250), AT vs. TT of IL10 (rs1800890), AG vs. GG of
IL10 (rs1800896), AG vs. AA of NOS2A (rs2297518), and
GG vs. AA of PPARG (rs709158). Genotype frequencies
did not differ by sex except for TNF (rs1799724), IL2
(rs2069762), IL10 (rs1800890), PPARG (rs1801282),
and CRP (rs1800947) with differences of no more than
4% between two groups (Table 4; see Additional file 3).BMC Genetics 2007, 8:7 http://www.biomedcentral.com/1471-2156/8/7
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Discussion
We report allele frequencies and genotype frequencies in
a large community-based population, predominantly of
Caucasians. Although the CLUE cohorts were not enrolled
through a random sampling process, we find no particular
reason to suggest that the genetic composition of CLUE
participants would have affected research participation.
This notion is supported by the findings that the fre-
quency distributions of genetic polymorphisms did not
differ between the Odyssey and the CLUE II subcohort.
The similar allele frequencies in CLUE's Caucasians to the
frequencies reported from the SNP500Cancer database
have implications for the design of studies on genetic pol-
ymorphisms. When the SNP500Cancer database is used
as a source of reference for SNP selection with allele fre-
Table 1: Characteristics of the Odyssey and CLUE II subcohort study participants, Washington County, Maryland, 1989
Characteristic Total
N = 9,960
Odyssey
N = 8,307
Subcohort
N = 2,460
Age-adjusted OR (95%CI)*
Age (yrs)
Mean (SD) 53.2 (15.5) 55.6 (13.5) 45.7 (18.5) 1.04(1.04,1.05)†
Min, Max 5, 95 28, 95 5, 94
Median (IQR) 54 (42, 65) 56 (45, 66) 46 (32, 61)
Gender
Male 3829 (38) 3111 (37) 1035 (42) 1.0
Female 6131 (62) 5196 (62) 1425 (58) 1.22(1.11,1.35)
Race
White 9831 (99) 8213 (99) 2415 (98) 1.0
Black 105 (1) 81 (1) 34 (1) 0.95(0.63,1.44)
Others 24 13 11 0.48(0.21,1.14)
BMI (kg/m2)
< 25 4269 (43) 3392 (41) 1219 (50) 1.0
25 – 29.9 3758 (38) 3259 (39) 794 (32) 1.26(1.13,1.40)
=> 30 1921 (19) 1647 (20) 444 (18) 1.26(1.11,1.43)
Missing 12 9 3
Cigarette smoking
Never 5363 (54) 4474 (54) 1318 (53) 1.0
Former 2952 (30) 2545 (31) 669 (27) 0.90(0.81,1.01)
Current 1645 (17) 1288 (15) 473 (19) 0.91(0.80,1.04)
Education (years)
<12 2476 (25) 1994 (24) 680 (28) 1.0
=12 4555 (46) 3869 (47) 1038 (42) 1.65(1.47,1.86)
>12 2923 (29) 2439 (29) 741 (30) 1.50(1.32,1.71)
Missing 6 5 1
Blood pressure‡
Normal 2277 (23) 1719 (21) 705 (29) 1.0
Prehypertensive 4471(45) 3684 (44) 1159 (47) 0.95(0.84,1.07)
Hypertensive 3204 (32) 2896 (35) 595 (24) 0.95(0.83,1.09)
Missing 8 8 1
Cholesterol(mg/dl) with no treatment
< 200 4092 (44) 3223 (42) 1180 (50) 1.0
200 – 239 3472 (37) 2979 (38) 791 (33) 1.00(0.89,1.11)
>= 240 1773 (19) 1536 (20) 386 (16) 0.93(0.81,1.07)
Cholesterol(mg/dl) with treatment
< 200 119 (23) 108 (22) 21 (25) 1.0
200 – 239 223 (42) 205 (43) 33 (39) 1.19(0.65,2.15)
>= 240 184 (35) 168 (35) 30 (36) 1.05(0.57,1.93)
* age adjusted odds ratio of being an Odyssey cohort participant.
† per year increment.
‡ Normal blood pressure was defined as individuals with systolic pressure <120 mmHg and diastolic blood pressure of 80 mmHg and not on anti-
hypertensive medication; Hypertension was defined as under anti-hypertensive medication or systolic pressure >140 mmHg or diastolic pressure of 
90 mmHg. Individuals with systolic blood pressure between 120 and 140 mmHg and/or diastolic blood pressure between 80 mmHg and 90 mmHg 
were considered pre-hypertensive.BMC Genetics 2007, 8:7 http://www.biomedcentral.com/1471-2156/8/7
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quencies as one of the selection criteria, and if both wild-
type and variant alleles have fairly high frequencies
(30%–70%), even a discrepancy in allele frequency
between study samples and the samples used in the
SNP500Cancer project is up to 20% may not influence
investigators' decision on including into a particular SNP
into a study. However, for rarer alleles, sampling errors
resulting in variations in allele frequencies estimates can
have an impact on SNP selection. For example, we chose
to study a SNP (rs1726803) of POLD1 gene and a SNP
(rs6413413) of ADH2 gene that were reported on the
SNP500Cancer database to have a minor allele frequency
of 5%. After analyzing approximately 3,000 samples, we
found no variation in the SNP allele frequency and
stopped this genotyping analysis.
Among the 49 SNPs examined, 10 SNPs did not follow
the Hardy-Weinburg equilibrium. Genotyping is not
100% accurate and failures to call out genotypes might
have been a reason for the H-W disequilibrium. On the
other hand, the sample size is fairly large in this study, and
the larger the sample size is, the easier for any discrepancy
in the observed allele frequency from the expected fre-
quency (according to an H-W equilibrium) to reach statis-
tical significance.
Although in the present study, the number of African
American participants was limited (n = 105), it exceeded
the size reported on the SNP500Cancer databases (n =
24). As expected, there were greater differences in the
allele frequencies between the present study and the
SNP500Cancer database for African Americans; allele fre-
quencies significantly differed for 35% of the SNPs for
which comparisons could be made. This finding raises
concerns about the usefulness of the SNP500Cancer data-
base as a reference for candidate gene selection for African
Americans.
We observed sex- or age-differences in genotype frequen-
cies for some of the SNPs. Chance alone cannot be
excluded from being a possible explanation for the statis-
tically significant differences in genotype frequencies
between age groups or sex groups, particularly because the
differences in genotypes between age and sex groups were
small in the present study. Replication is needed for test-
ing the robustness of these findings.
Conclusion
In conclusion, when estimating the size of samples
needed for a study, particularly if a reference sample is
used, one should take into consideration the size and the
ethnicity of the reference sample. The greater differences
in allele frequencies among African Americans between
the present study and public databases indicate a need for
basing public databases on a larger sample size for this
ethnic group. The small differences in genotype frequen-
cies by age or sex for some candidate genes may be
explained by chance alone, and more published data are
needed for replication.
Methods
Study population
The study population consists of participants in two com-
munity-based cohorts, CLUE I and CLUE II, in Washing-
ton County, Maryland. Washington County has a slowly
growing population. The majority (98%) of the Washing-
ton County residents is Caucasian; 1.5% are African Amer-
icans. CLUE I (from a slogan, give us a CLUE to cancer and
heart disease) was established in 1974 for the purposes of
collecting brief questionnaire data and setting up a serum
bank for research purposes. Participants were recruited at
mobile trailers that were stationed in various locations in
Washington County to offer opportunities for research
participation. A total of 26,147 individuals participated in
CLUE I. Of these, 23,951 were Washington County resi-
dents. Participation was better in women, in those who
had more years of education and in the age group of 45–
64 years.
The CLUE II was a similar campaign conducted in 1989 in
which plasma samples, buffy coat samples and informa-
tion on participants' selected characteristics and diet were
collected. A total of 32,896 individuals participated in
CLUE II, and of these, 25,079 were Washington County
residents. Both CLUE I and CLUE II cohorts included
approximately 30% of the County residents. The racial
distributions of the CLUE I and CLUE II cohorts were sim-
ilar to that in the Washington County. CLUE II participa-
tion was slightly better among women, among those who
had more years of school education, and among those
who were at age of 45–70 years.
The present study includes the Odyssey cohort and a
CLUE II subcohort. The Odyssey cohort is composed of
the 8,394 individuals who took part in both CLUE I and
CLUE II. Within Odyssey, DNA was successfully extracted
from the buffy coat samples of 8,307 individuals. The
CLUE II subcohort (n = 2,460) is an age- and sex-stratified
random sample (10%) of the CLUE II participants who
were residents of Washington County and its neighboring
areas. DNA samples from this subcohort were successfully
extracted from all buffy coat samples. Among these, 807
samples overlapped with the 8,307 Odyssey samples.
Hence, 9960 samples are included in the present study.
SNP data were rendered anonymous by in-house Anony-
mous Data Management software. The study identifiers
were encrypted by modern cryptographic technologies
that destroyed the link from genetic information back to
identities, while anonymously allowing one-way linkageBMC Genetics 2007, 8:7 http://www.biomedcentral.com/1471-2156/8/7
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from identities to genetic information. Informed content
to take part in the CLUE I and CLUE II research campaign
was obtained from each participant. The protocol was
approved by the Institutional Review Board of the Johns
Hopkins Bloomberg School of Public Health.
Selection of candidate genes
Candidate genes were selected based on the following cri-
teria: (a) estimated allele frequencies of ≥ 5% in Cauca-
sians in published literature or databases, (b) known or
promising importance in the development of cancer, car-
diovascular diseases, and/or longevity, (c) validated allele
substitutions, and/or (d) functional changes linked to
allele substitutions that have been published in the litera-
ture.
Laboratory analysis
At CLUE II enrollment, blood samples were collected into
20-ml heparinized Vacutainers (Fisher Scientific, Pitts-
burgh, PA). Samples were refrigerated at 4°C and most
samples were centrifuged within 2 to 6 hours after blood
collection and were never 24 hours later. Plasma aliquots
from each participant were placed in two 5-ml Cryotubes
(Sumitomo Bakelite, Neptune, NJ) and were stored at -
70°C. Buffy coat samples were stored in separate vials at -
70°C until extraction. Barcoding was performed as part of
the blood collection process. Labels were printed with the
study numbers barcoded so that they could be scanned for
accuracy in data entry and inventory maintenance.
DNA was extracted from buffy coat by the alkaline lysis
method [22]. Following isolation, DNA samples were
resuspended in 10 mM Tris-HCl/1 mM EDTA (TE) and
DNA concentration was adjusted to 100 μg/ml. Genotyp-
ing was performed by Celera Genomics Co. (Rockville,
DC) for the 17 SNPs with rs numbers 1799864, 333,
1800629, 1800587, 1143634, 16944, 2243250,
1800795, 4073, 1800871, 1800872, 2143416, 2745557,
2206593, 4684847, 709158, and 1175543, and subse-
quently by Applied Biosystems Inc. (Foster City, CA) for
the 32 SNPs with rs numbers 3842787, 5275, 1205,
1800947, 1130864, 2794521, 105885, 1469149, 25882,
2069705, 17561, 2069762, 1800797, 1800890,
1800896, 20541, 1800925, 187238, 1946518, 2857713,
3093543, 1041981, 909253, 2243828, 2333227,
2297518, 1799983, 2016520, 1801282, 8192678,
1799724, and 1799964. Both laboratories used the Taq-
Man assay.
Assay reliability was assessed for the 17 SNPs analyzed by
Celera, using 86 duplicate samples randomly inserted into
the plates; the percent concordance was 82–95%. Two
SNPs (rs 1800587 and rs 17561) were both analyzed by
Celera and ABI. The percent concordance was 0.89 and
0.90, respectively.
Statistical analysis
Characteristics of the Odyssey and the CLUE II subcohort
study participants were summarized by the frequency dis-
tributions of categorical variables and by the means (SDs)
of continuous variables. The genotype frequencies of each
candidate gene were compared between the Odyssey and
the CLUE II subcohort. For most SNPs, no differences in
genotype frequencies were observed between the Odyssey
and the subcohort. The only exceptions were LTA
(rs3093543) for which a higher proportion of AC as com-
pared to AA genotype was observed [OR = 1.18 (1.05,
1.32)] and PPARGC1 (rs8192678) for which a higher pro-
portion of AA as compared to GG genotype was observed
[OR = 1.28 (1.08, 1.51)] in the Odyssey compared to the
subcohort. Subsequent analyses were performed on the
combined Odyssey and subcohort data.
Allele frequencies were examined separately in Caucasians
and African Americans, and were compared to the fre-
quencies reported from the SNP500Cancer database or if
unavailable from SNP500Cancer, the dbSNP database.
Statistically significant differences were reported if the
allele frequencies from public databases fell beyond the
95% confidence intervals (95% CIs) of the allele frequen-
cies among the CLUE population. The Hardy-Weinberg
equilibrium was tested by a goodness-of-fit approach.
Genotype frequencies by age groups of 10-year intervals
were examined. Because age as a continuous variable pro-
vides more information, the One-Way Analysis Of Vari-
ance (ANOVA), rather than χ2 tests for age categories by
genotypes, was used to compare age as continuous varia-
ble across the genotype categories. Genotype frequencies
were compared between men and women by χ2 test.
Abbreviations
IL: interleukins; TNFs: tumor necrosis factors; COX:
cyclooxygenase; NOS: nitric oxide synthase; PPARs: per-
oxisome proliferator-activated receptors; CCR: chemokine
receptors, MPO: myeloperoxidase; IFNG: interferon-
gamma; CSF: colony-stimulating factors; LTA: lympho-
toxin alpha; CRP: C-reactive protein.
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